PATENT CLAIM ANALYSIS

Application Number: 15957469
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "170000"]

Abstract:
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

Claim (Index 22):
The method according to  claim 21  wherein said first dosing schedule comprises the administration of elagolix at 300 mg b.i.d. and wherein said second dosing schedule comprises the administration of less than 300 mg per dose and/or dosing less than twice per day.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 91.0
- Lexical Diversity: 1.62162
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15254419', '11715509', '15719636', '13128459', '10948608']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7169238815834792
- 35 USC 102 Novelty (BERT): 0.6707391126210751
- Combined Prediction Score: 0.7123054046872388
- Mean Citation Score: 298.140414
- Max Citation Score: 637.58734
- Similarity Product: 635.2330818128454

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test